Shingles (Herpes Zoster) Vaccine Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
Conditions: Herpes Zoster Interventions: Biological: HZ Vaccine (IN001); Biological: Placebo; Biological: Shingrix Sponsors: Shenzhen Shenxin Biotechnology Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials

A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years
Conditions: Herpes Zoster Interventions: Biological: LYB004 25 µg; Biological: LYB004 50µg; Biological: SHINGRIX Sponsors: Guangzhou Patronus Biotech Co., Ltd.; Yantai Patronus Biotech Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials

Multidisciplinary Hospital-Territory Vaccine Center: a Model for Achieving the Herpes Zoster Vaccine Coverage
Conditions: Herpes Zoster Interventions: Biological: Herpes Zoster adjuvanted recombinant vaccine Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials

Nudging Patients to Increase Shingles Vaccination
Conditions: Shingles; Vaccination Behavior; Behavior, Health Interventions: Behavioral: Reminder Sponsors: Geisinger Clinic; Massachusetts Institute of Technology; National Bureau of Economic Research, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials

Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above
Conditions: Vaccine-Preventable Diseases; Herpes Zoster Interventions: Biological: CVI-VZV-001; Biological: Shingrix Sponsors: CHA Vaccine Institute Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials

A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine
Conditions: Vaccine-Preventable Diseases; Herpes Zoster Interventions: Biological: Recombinant Herpes Zoster Vaccine; Biological: Recombinant Herpes Zoster Vaccine Placebo Sponsors: Beijing Luzhu Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 18, 2023 Category: Research Source Type: clinical trials

Study to Evaluate the Immune Response, Safety, and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co-administered With Herpes Zoster Recombinant Subunit (HZ/su) Vaccine Adults Aged 50 Years and Older
Condition: Respiratory Syncytial Viruses Interventions: Biological: RSVPreF3 OA investigational vaccine; Biological: HZ/su vaccine Sponsor: GlaxoSmithKline Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 28, 2023 Category: Research Source Type: clinical trials

First Subject Dosed in a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Vaccine Developed for the Prevention of Shingles
MORRISVILLE, N.C., May 30, 2023. Immorna, a rapidly expanding biotechnology company focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the first subject has been dosed in the Company ' s... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 30, 2023 Category: Pharmaceuticals Source Type: clinical trials